How should leukocytosis be evaluated and managed in a patient with COVID‑19?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Leukocytosis in COVID-19: Evaluation and Management

Leukocytosis in COVID-19 patients is a critical prognostic marker that signals severe disease and requires immediate evaluation to distinguish between COVID-19-related inflammatory response, secondary bacterial infection, and underlying hematologic malignancy.

Clinical Significance and Prognostic Value

Leukocytosis in COVID-19 is strongly associated with disease severity and mortality. Leukocytosis is one of the strongest predictors of critical COVID-19, with an odds ratio of 3.866 for critical disease 1. Similarly, leukocytosis carries a crude odds ratio of 37.1 for death in hospitalized COVID-19 patients 2. This elevation typically reflects neutrophilia and indicates progression to the inflammatory phase of disease.

Initial Evaluation Approach

When encountering leukocytosis in a COVID-19 patient, immediately assess:

1. Determine the Pattern of Elevation

  • Neutrophilic leukocytosis with left shift: Most common in severe COVID-19, indicates inflammatory phase 2
  • Neutrophil-to-lymphocyte ratio (NLR) ≥ 9: Associated with 13.5-fold increased odds of death 2
  • Extreme leukocytosis (>50 × 10⁹/L): Consider leukemoid reaction or underlying leukemia 3, 4
  • Presence of blasts or immature cells: Mandates immediate hematology consultation for possible acute leukemia 4

2. Assess Disease Severity Markers

  • C-reactive protein >100 mg/L (OR 17.8 for death) 2
  • Oxygen saturation, respiratory rate, need for supplemental oxygen
  • Lactate dehydrogenase elevation
  • Evidence of tumor lysis syndrome if extreme leukocytosis present 4

3. Rule Out Secondary Infections

  • Bacterial pneumonia or sepsis (most common cause of leukocytosis beyond COVID-19 inflammation)
  • Fungal infections, particularly mucormycosis in patients with diabetes or steroid use 5

Management Strategy

For Leukocytosis Due to Severe COVID-19 Inflammation:

Initiate anti-inflammatory therapy when leukocytosis accompanies oxygen requirement and elevated inflammatory markers 6, 7:

  • Dexamethasone 6 mg daily for 10 days as first-line anti-inflammatory therapy 7
  • Add tocilizumab or baricitinib if inflammation worsens despite steroids and no contraindications (active bacterial/fungal infection) 6
  • Continue antiviral therapy with remdesivir or nirmatrelvir/ritonavir 6

Critical caveat: Do not use steroids if leukocytosis is due to bacterial co-infection or fungal infection, as this will worsen outcomes 6.

For Extreme Leukocytosis (>50 × 10⁹/L):

If peripheral smear shows blasts or immature myeloid cells:

  • Immediate hematology consultation for possible acute leukemia 4
  • Initiate hydroxyurea for cytoreduction if hyperleukocytic AML confirmed 4
  • Tumor lysis prophylaxis with allopurinol and aggressive hydration 4
  • Transfer to tertiary oncology center for definitive therapy 4

The case report of AML presenting with hyperleukocytosis during COVID-19 infection highlights that viral infections may unmask previously undiagnosed leukemia 4, making peripheral smear review mandatory in extreme leukocytosis.

For Leukemoid Reaction:

If WBC >50 × 10⁹/L with left shift but no blasts:

  • Exclude hematologic malignancy with peripheral smear review 3
  • Treat underlying severe COVID-19 as above
  • Monitor for resolution as COVID-19 improves 3

Special Populations: Hematologic Malignancy Patients

In patients with known or suspected hematologic malignancy:

Defer intensive chemotherapy for at least 14 days or until COVID-19 symptoms significantly improve in moderate-severe disease 6. However, for mild COVID-19 or asymptomatic SARS-CoV-2 infection, personalize decisions based on:

  • Remission status of underlying malignancy
  • Urgency of chemotherapy
  • Availability of early COVID-19 treatment interventions 6

Maintain non-chemotherapy targeted drugs (JAK inhibitors, TKI, BTK inhibitors) during COVID-19 treatment 6.

Key Pitfalls to Avoid

  • Do not assume all leukocytosis is COVID-19-related: Always review peripheral smear to exclude leukemia, especially with extreme elevations 4
  • Do not give steroids empirically: Confirm COVID-19 inflammatory phase (oxygen requirement + elevated CRP) and exclude active bacterial/fungal infection first 6, 7
  • Do not delay hematology consultation: Hyperleukocytic leukemia is a medical emergency requiring immediate cytoreduction 4
  • Do not overlook mucormycosis: Leukocytosis with neutrophilia in diabetic or steroid-treated COVID-19 patients warrants evaluation for invasive fungal infection 5

References

5
Research

Hematological Indices in COVID-19 Patients with Rhinosinusitis Mucormycosis.

Iranian journal of otorhinolaryngology, 2024

Related Questions

Interpret the CBC showing leukocytosis with neutrophilia, lymphopenia, anemia, and increased red cell distribution width: what is the likely etiology and recommended management?
Should a repeat complete blood count (CBC) be performed for a patient with mild leukocytosis and neutrophilia?
Should a 67-year-old female with marked leukocytosis (WBC 19,000) and neutrophilia, afebrile, stable vital signs, sterile urine culture, and a large right renal mass extending into Gerota’s fascia and involving the adrenal gland be cleared for right-sided nephrectomy?
What is the appropriate evaluation and management for a 32‑year‑old man presenting with right‑leg cramps and leukocytosis (white blood cell count 12.7 ×10⁹/L) with an absolute neutrophil count of 10,688/µL?
How should a 38-year-old patient with mid‑abdominal pain, nausea, leukocytosis, and contrast‑enhanced CT showing diffuse colonic wall thickening be managed?
When are antibiotics indicated in an acute asthma exacerbation?
What antihypertensive medication is more potent than lisinopril 40 mg for controlling blood pressure?
In an adult with triglycerides of 260 mg/dL and LDL cholesterol of 119 mg/dL, should fenofibrate be started?
Are there any drug interactions between carvedilol and amiodarone?
What is the recommended management for a patient with chronic kidney disease and secondary hyperparathyroidism, whose labs show 25‑hydroxyvitamin D 76 ng/mL, 1,25‑dihydroxyvitamin D 27 pg/mL, and parathyroid hormone 179 pg/mL?
What additional laboratory tests are needed 8 weeks after intravenous iron infusion?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.